OncoMed
private limited liability company
OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
0
confidence 85 % · metrics-v1
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
0
confidence 60 % · metrics-v1
Corporate Change Index
2.9
confidence 64 % · cci-v1
9 active sensors·7 observations·0 historical changes·0 structured events·historical coverage 100 %·observed since 2026-09-14
Compare OncoMed with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies